17325-26-7

Basic information

• Product Name: Methyl 4-imidazolecarboxylate
• Synonyms: RARECHEM AL BF 0762;METHYL IMIDAZOLE-4-CARBOXYLATE;METHYL 4-IMIDAZOLECARBOXYLATE;Methyl 1H-imidazole-4-carboxylate;1H-Imidazole-4-carboxylic acid methyl ester;3H-Imidazole-4-carboxylic acid methyl ester;Methyl 4-imidazolecarboxylate,98%;Methyl 4-imidazolecarboxylate ,99%
• CAS NO: 17325-26-7
• Molecular Formula: C₅H₆N₂O₂
• Molecular Weight: 126.11
• EINECS: 1312995-182-4
• Product Categories: pharmacetical;Heterocyclic Compounds;Heterocycle;Building Blocks;Heterocyclic Building Blocks;Imidazoles;Building Blocks;Chemical Synthesis;Heterocyclic Building Blocks
• Mol File: 17325-26-7.mol

Chemical Properties

• Melting Point: 154-156 °C(lit.)
• Boiling Point: 318.2 °C at 760 mmHg
• Flash Point: 146.2 °C
• Appearance: White/Crystalline Powder
• Density: 1.275 g/cm³
• Vapor Pressure: 0.000368mmHg at 25°C
• Refractive Index: 1.53
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 10.89±0.10(Predicted)
• CAS DataBase Reference: Methyl 4-imidazolecarboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: Methyl 4-imidazolecarboxylate(17325-26-7)
• EPA Substance Registry System: Methyl 4-imidazolecarboxylate(17325-26-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 17325-26-7(Hazardous Substances Data)

Usage

Uses

Used in Chemical Synthesis:
Methyl 4-imidazolecarboxylate is used as a starting material for the synthesis of various organic compounds. Its reactivity and structural features make it a valuable precursor in the production of different chemical entities.
Methyl 4-imidazolecarboxylate is used as a starting material for the synthesis of:
1. 1-(3-prop-1-enyl)-imidazole-4-carboxyaldehyde, which is an important intermediate in the production of various imidazole-based compounds with potential applications in pharmaceuticals and materials science.
2. Osmium(2,2′-bipyridyl)2(methyl 4-imidazolcarboxylate)dichloride, a complex compound that may find use in the field of coordination chemistry and catalysis.

InChI:InChI=1/C5H6N2O2/c1-9-5(8)4-2-6-3-7-4/h2-3H,1H3,(H,6,7)

Upstream product

• 67-56-1 methanol 
• 1072-84-0 3H-imidazole-4-carboxylic acid 
• 97602-55-6 methyl (Z)-3-(tetrazol-1-yl)propenoate 
• 3034-50-2 4⁽⁵⁾formylimidazole 
• 186581-53-3 diazomethane 
• 1072-84-0 imidazole-4-carboxylic acid 
• 31458-33-0 5-methoxypyrimidine 

Downstream Products

• 91736-11-7 1(3)H-imidazole-4-carboxylic acid propylamide 
• 81797-92-4 <4(5)-imidazolyl>diphenylmethanol 
• 53525-55-6 1⁽³⁾H-imidazole-4-carboxylic acid methylamide 
• 18329-78-7 1H-imidazole-4-carboxylic acid hydrazide 
• 878479-17-5 1-(2,2-dimethyl-6-trityloxymethyl-4,6a-dihydro-3aH-cyclopenta[1,3]dioxol-4-yl)-1H-imidazole-4-carboxylic acid methyl ester 
• 314061-15-9 1-(3-nitro-phenyl)-1H-imidazole-4-carboxylic acid methyl ester 
• 86347-06-0 4-[α,α-bis(2-methylphenyl)hydroxymethyl]imidazole 
• 1214282-40-2 methyl 1-[2-hydroxy-3-(4-octylphenoxy)propyl]imidazole-4-carboxylate 
• 1214282-42-4 methyl 1-[2-hydroxy-3-(4-octylphenoxy)propyl]imidazole-5-carboxylate 
• 116343-89-6 methyl 1-phenyl-1H-imidazole-4-carboxylate 
• 1202207-15-5 methyl 1-(3,5-dibromo-4-methoxyphenyl)-1H-imidazole-4-carboxylate 
• 1308719-82-5 methyl 1-[((2S)-1-4-[(benzyloxy)carbonyl]benzyl-5-oxotetrahydro-1H-pyrrol-2-yl)methyl]-1H-imidazole-4-carboxylate 
• 1308719-69-8 methyl 1-[((2S)-1-4-[(benzyloxy)carbonyl]benzyl-5-oxotetrahydro-1H-pyrrol-2-yl)methyl]-1H-imidazole-5-carboxylate 
• 1308719-77-8 4-[((2S)-2-[5-(methoxycarbonyl)-1H-imidazol-1-yl]methyl-5-oxotetrahydro-1H-pyrrol-1-yl)methyl]benzenecarboxylic acid 

Relevant articles and documents

Synthesis and antiproliferatory activity of ruthenium complexes containing N-heterocyclic carboxylates

Solvates of the complexes Ru2Cl(pic)4(EtOH) (2), Ru(Im-CO2)3 (3), and Ru(Im-CO2)(Im-CO2H)Cl2 (4), were synthesized from reaction of RuCl3·3H2O or K3[RuCl6] with the N-heterocyclic carboxylic acids pyridine-2-carboxylic acid (picolinic acid, Hpic), and imidazole-4-carboxylic acid (Im-CO2H). Crystals of 2–4 could not be grown and hence characterization was done by elemental analysis, NMR, IR, and conductivity data; 2 and 4 were tested for antiproliferatory activity in vitro against a human breast cancer cell line, but were less active than, for example, Ru complexes containing bis-imidazole or 4,4′-biimidazole that we studied previously [see Can. J. Chem. 89 (2011) 948]. Preliminary work with a third potential ligand, 3-nitro-1,2,4-triazole-5-carboxylic acid (abbreviated HCANT), and other nitro heterocyclic compounds is also presented.

IRAK DEGRADERS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same.

Tripterine imidazole derivative as well as preparation method and application thereof

The invention discloses a novel tripterine imidazole derivative as well as a preparation method and application thereof, and belongs to the field of biomedicine. The tripterine imidazole derivative has a structure shown as a formula I as shown in the specification, wherein R1, R2 and R3 are respectively selected from H, alkyl, hetero-atomic alkyl, halogen or nitryl; and X is selected from a saturated or unsaturated linear aliphatic hydrocarbon fragment containing 3-6 carbon atoms. The novel tripterine imidazole derivative as well as the preparation method and the application thereof disclosedby the invention have the benefits that the preparation method of the compound is mild in reaction conditions; a used reagent is low in toxicity, raw materials are easy to obtain, the post-treatment is convenient, and the yield is relatively high. Pharmacological experiment studies shows that the compound has excellent anti-tumor activity and can be applied to the preparation of an anti-tumor drug.

PDE9 INHIBITORS FOR TREATMENT OF PERIPHERAL DISEASES

The present invention relates to PDE9 inhibitors, their synthesis, and their use for treatment of benign prostate hyperplasia, beta thalassemia, and sickle cell disease.

Intermediate for preparing medetomidine and its preparation method and use

The invention provides an intermediate for preparing medetomidine. The intermediate is a compound shown in the formula (I). The invention also provides a preparation method of the intermediate, and ause of the intermediate in the preparation of medetomidine. The compound shown in the formula (I) is used for preparation of medetomidine so that the raw material is cheap and easy to obtain, synthesis processes are simple, the reaction cycle is short, the environmental pollution is avoided, operation is simple, the harsh reaction conditions are avoided, the operation and post-treatment are simple, the yield and the product purity are high, the intermediate in each step is a solid and is easy to purify, a production cost is low, and the intermediate is suitable for industrial large-scale production and conforms to the principle of green chemistry.

PDE9 INHIBITORS WITH IMIDAZO TRIAZINONE BACKBONE AND IMIDAZO PYRAZINONE BACKBONE FOR TREATMENT OF PERIPHERAL DISEASES

The present invention relates to PDE9 inhibitors and their use for treatment of benign prostate hyperplasia and sickle cell disease.

An efficient one-pot oxidative esterification of aldehydes to carboxylic esters using B(C6F5)3-TBHP

A simple and efficient protocol for oxidative esterification of diverse aldehydes with alcohols was accomplished with tert-butyl hydroperoxide and 1 mol % of tris(pentafluorophenyl)borane [B(C6F5)3] to generate the corresponding esters in good to excellent yields. The present protocol represents compatibility with wide range of functional groups as well as exceptional tolerance toward acid labile protecting groups such as TBDPS, TBDMS, acetonide, and Boc.

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

Compounds of formula (I) or (II) wherein Rx, Rz, R9, R10, R14, R14′, R15, R15′, A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

ANDROGEN RECEPTOR MODULATING CARBOXAMIDES

Compounds of formula (I) wherein Rx, Rz, R9, R10, R14, R14', R15, R15', A and B are as defined in the claims and pharmaceutically acceptable salts and esters thereof, are disclosed. The compounds possess utility as tissue-selective androgen receptor modulators (SARM) and are particularly useful as medicaments in the treatment of prostate cancer and other AR dependent conditions and diseases where AR antagonism is desired.

Imidazole Derivative

To provide a novel compound or an isotope thereof or a pharmaceutically acceptable salt thereof having S1P lyase inhibitory capacity and inducing the decrease in number of lymphocytes, and a pharmaceutical composition containing these as active ingredients. A compound represented by the general formula (I): or the general formula (II): or an isotope thereof or a pharmaceutically acceptable salt thereof.